BLACK FRIDAY

ADVFN

Celebrando 25 años Est 1999-2024

Ahorra hasta 60%* en Forex

1 año 40%, 2 años 40% y *3 años 60%

*Durante 3 años $1.035.00 solo $414.00

ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,021.63
0.57%
Dow Jones
44,860.31
0.28%
US Dollar vs MXN
20.6817
0.07%
Brent Oil
72.735
0.39%
Bitcoin
93,224.40
1.36%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Verve Therapeutics Inc (VERV) Cotización

Verve Therapeutics Inc

Verve Therapeutics Inc (VERV)

Verbund Ag
Verbund Ag
Verbund Ag
Verbund Ag
5.31
0.02
(0.38%)
Cerrado 26 Noviembre 3:00PM
Delayed by 15 minutes
5.31
0.00
( 0.00% )
Pre Mercado: 3:00AM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Estadísticas y detalles clave

Último Precio
5.31
Postura de Compra
4.85
Postura de Venta
5.59
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
4.305 Rango de 52 semanas 19.34
Capitalización de Mercado [m]
449.565M
Precio Anterior
5.31
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
1,332,147
Acciones en circulación
84,663,840
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-2.25
Beneficio por acción (BPA)
-2.36
turnover
11.76M
Beneficio neto
-200.07M

Acerca de Verve Therapeutics Inc

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively... Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.vervetx.com
Sede
Wilmington, Delaware, USA
Fundado
-
Verve Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VERV. The last closing price for Verve Therapeutics was US$5.31. Over the last year, Verve Therapeutics shares have traded in a share price range of US$ 4.305 to US$ 19.34.

Verve Therapeutics currently has 84,663,840 shares in issue. The market capitalisation of Verve Therapeutics is US$449.56 million. Verve Therapeutics has a price to earnings ratio (PE ratio) of -2.25.

VERV Últimas noticias

Más noticias

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

08 Noviembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

05 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

05 Noviembre 2024
Edgar (US Regulatory)

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results

Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025 First participant dosed in the...

05 Noviembre 2024
GlobeNewswire Inc.

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON , Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October...

01 Noviembre 2024
GlobeNewswire Inc.

Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV

Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV PR Newswire LOS ANGELES, Oct. 28, 2024 LOS ANGELES, Oct. 28, 2024 /PRNewswire/...

28 Octubre 2024
PR Newswire (US)

Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - VERV

Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - VERV PR Newswire NEW YORK, Oct. 28, 2024 NEW YORK, Oct...

28 Octubre 2024
PR Newswire (US)

Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV

Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV PR Newswire LOS ANGELES, Oct. 23, 2024 LOS ANGELES, Oct. 23, 2024 /PRNewswire/...

23 Octubre 2024
PR Newswire (US)

Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV

Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV PR...

17 Octubre 2024
PR Newswire (US)

Class Action Filed Against Verve Therapeutics, Inc. (VERV) - October 28, 2024 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Verve Therapeutics, Inc. (VERV) - October 28, 2024 Deadline to Join - Contact The Gross Law Firm PR Newswire NEW YORK, Oct. 14, 2024 NEW YORK, Oct. 14, 2024...

14 Octubre 2024
PR Newswire (US)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.479.710743801654.845.484.4414732334.95155854CS
4-0.635-10.68124474355.9456.774.4416704185.57292776CS
12-0.63-10.60606060615.946.774.3913321475.41757822CS
26-0.06-1.117318435755.377.964.30513856225.54049986CS
52-7.11-57.246376811612.4219.344.30513414968.1310959CS
156-28.62-84.35013262633.93434.305103458015.8078253CS
260-24.69-82.330784.30595351917.86089305CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
HWHHWH International Inc
US$ 1.195
(111.50%)
3.04M
IFBDInfobird Company Ltd
US$ 2.93
(60.99%)
692.3k
IDAIT Stamp Inc
US$ 0.5378
(47.34%)
5.48M
CYCNCyclerion Therapeutics Inc
US$ 1.83
(34.56%)
295.31k
QMCOQuantum Corporation
US$ 21.89
(27.05%)
73.55k
PGHLPrimega Group Holdings Ltd
US$ 11.85
(-88.96%)
117.17k
NVXNOVONIX Ltd
US$ 2.00
(-25.65%)
87
IMGCIMG Inc
US$ 1.20
(-25.00%)
105.85k
LEGHLegacy Housing Corporation
US$ 20.00
(-22.78%)
99
ALRSAlerus Financial Corporation
US$ 17.00
(-22.66%)
200
IDAIT Stamp Inc
US$ 0.5373
(47.21%)
5.48M
HWHHWH International Inc
US$ 1.20
(112.39%)
3.04M
RGTIRigetti Computing Inc
US$ 2.47
(12.27%)
2M
IFBDInfobird Company Ltd
US$ 2.93
(60.99%)
692.58k
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 20.75
(0.83%)
326.72k

VERV Discussion

Ver más
Monksdream Monksdream 3 meses hace
VERV new 52 week low
👍️0
Monksdream Monksdream 3 meses hace
VERV new 52 week low
👍️0
Monksdream Monksdream 4 meses hace
VERV 10Q due AUGUST5
👍️0
Monksdream Monksdream 5 meses hace
VERV new 52 week low
👍️0
Monksdream Monksdream 5 meses hace
VERV new 52 week low
👍️0
Monksdream Monksdream 6 meses hace
VERV more new lows up ahead
👍️0
Monksdream Monksdream 6 meses hace
VERV new 52 week low
👍️0
Monksdream Monksdream 7 meses hace
VERV new 52 week low
👍️0
Monksdream Monksdream 7 meses hace
VERV new 52 week low
👍️0
Monksdream Monksdream 7 meses hace
VERV new 52 week low
👍️0
Monksdream Monksdream 7 meses hace
VERV new 52 lo
👍️0
Firestorm22 Firestorm22 8 meses hace
uh oh
👍️0
Monksdream Monksdream 8 meses hace
VERV over $10
👍️0
fink fink 9 meses hace
Looking for an entry now
👍️0
Terpi Terpi 1 año hace
Could see another nice move here is the 50 day holds into close.
👍️0
Monksdream Monksdream 1 año hace
VERV morning rally
👍️0
TheFinalCD TheFinalCD 2 años hace
https://cathiesark.com/
👍️0
crudeoil24 crudeoil24 2 años hace
VERV IS A GREAT $$$$$ OPPORTUNITY.
👍️0
crudeoil24 crudeoil24 2 años hace
Verve Therapeutics started at outperform with $48 stock price target at BMO Capital
👍️0
crudeoil24 crudeoil24 2 años hace
Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
👍️0

Su Consulta Reciente

NASDAQ
VERV
Verve Therapeutics
BIT
ACAESE
Acomea Patrimonio Esente...
BIT
1DASH
DoorDash
BIT
1CNC
Centene
BIT
P12822
Bnp Paribas Issuance
BOV
R1OK34
Rockwell Automation
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados

BLACK FRIDAY

ADVFN

Celebrando 25 años Est 1999-2024

Ahorra hasta 60%* en Forex

1 año 40%, 2 años 40% y *3 años 60%

*Durante 3 años $1.035.00 solo $414.00